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Background: Recent genomic evidence suggests frequent phosphatidylinositide 3-kinase (PI3K) pathway activation
in human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. Mutations/amplification of the
gene encoding p110α catalytic subunit of phosphoinositide 3-kinase (PIK3CA), loss of phosphatase and tensin
homolog (PTEN) and HRAS mutations are known to activate PI3K pathway.
Methods and results: PIK3CA mutations were identified by Sanger sequencing in 23 of 75 (31%) HPV-positive
oropharyngeal carcinomas, including exon 9 (p.E545K [n = 10] and p.E542K [n = 5]) or exon 20 (p.H1047Y, n = 2)
mutations. Five rare and one novel (p.R537Q) PIK3CA mutations were identified. HRAS mutation (p.Q61L) was
detected in 1 of 62 tested cases. PIK3CA amplification by fluorescence in situ hybridization (FISH) was identified in 4
cases (4/21, 20%), while PTEN loss was seen in 7 (7/21, 33%) cases (chromosome 10 monosomy [n = 4],
homozygous deletion [n = 3]).
Conclusions: Overall, genetic alterations that likely lead to PI3K pathway activation were identified in 34 of 75 cases
(45%) and did not correlate with disease specific survival. These findings offer a molecular rationale for therapeutic
targeting of PI3K pathway in patients with HPV-positive oropharyngeal carcinoma.
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The phosphatidylinositide 3-kinase (PI3K) pathway is
activated in about half of head and neck squamous cell
carcinomas (SCC) by a number of mechanisms, including
mutation or amplification of the gene encoding p110α
catalytic subunit of phosphoinositide 3-kinase (PIK3CA)
[1-4]. The higher incidence of PI3K pathway activation in
oropharyngeal SCC was previously reported [5]. Oropha-
ryngeal SCC are increasingly associated with human papil-
lomavirus (HPV) infection [6,7] and the higher prevalence
of PI3K pathway abnormalities in these tumors was
eventually linked to HPV [8,9].
Most recent characterization of the mutational landscape
of head and neck SCC showed that the genetic profile of
HPV-positive SCC is distinct from that of HPV-negative
SCC. For instance, HPV-positive oropharyngeal SCC
harbor fewer mutations overall (e.g., no TP53 mutations)* Correspondence: chioseasi@upmc.edu
1Department of Pathology, University of Pittsburgh, 200 Lothrop St,
Pittsburgh, PA 15213, USA
Full list of author information is available at the end of the article
© 2013 Chiosea et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand more PIK3CA mutations. Specifically, of the 15
HPV-positive SCC with known PIK3CA status reported
in the literature, 4 tumors harbored PIK3CA mutation
(4/15, 27%) [10,11]. In contrast, PIK3CA mutations are
present in about 5% (5/91) of HPV-negative head and
neck SCC. The higher incidence of PIK3CA mutations
in HPV-positive SCC suggests a new therapeutic option, as
PI3K pathway is targeted by multiple drugs in development:
PX-866 [12], and MK-2066 [13], and RAD001 [14]. Indeed,
our most recent findings demonstrated that HPV-positive
SCC tumorgrafts with activating PIK3CA mutation were
highly responsive to PI3K-targeted therapy [15].
Increased PI3K signaling can also result from mutations
in other genes in the PI3K pathway such as HRAS [16,17].
In addition to PIK3CA mutations and/or amplification,
PI3K pathway may also be activated due to phosphatase
and tensin homolog (PTEN) deletion, a known negative
regulator of the PI3K signaling pathway [18].
The aim of the present study was to elucidate the
molecular basis for therapeutic targeting of PI3K pathway
in HPV-positive oropharyngeal SCC by characterizing thel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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HRAS mutations, PIK3CA amplification, and PTEN loss in
75 patients with HPV-positive oropharyngeal SCC.
Methods
Patients
This study was approved by the Institutional Review
Board of the University of Pittsburgh Medical Center
(IRB# PRO11010195). Seventy five cases of HPV-positive
oropharyngeal SCC were identified from 1983 to 2007 and
satisfied the following inclusion criteria: availability of
formalin fixed paraffin embedded tissue, p16 immuno-
histochemistry and HPV in situ hybridization positivity,
presence of tumor areas with >50% represented by cancer
cells, and extraction of adequate DNA.
HPV in situ hybridization and p16 immunohistochemistry
HPV detection by in-situ hybridization was performed
using probes targeting 37 distinct HPV subtypes, including
6, 11, 16, 18, 31, 33, 35, 39, 45, 51, and 52 (Y1404; Dako,
Carpinteria, CA). Five-micrometer tissue sections were
deparaffinized and digested with proteinase K (Roche
Diagnostics, Indianapolis, IN). Cases with punctate nuclear
signal were considered positive [19].
For p16 analysis, five-micrometer sections were depar-
affinized. Heat-induced epitope retrieval was then per-
formed in a citrate buffer. Immunohistochemistry for
p16 (G175-405; BD Pharmingen, San Diego, CA) was
performed as per the manufacturer’s protocol. Cases
were considered positive if >70% of tumor cells showed
diffuse and strong cytoplasmic and nuclear staining [19].
PIK3CA and HRAS mutation analysis
Tissue cores from tumor targets were obtained as pre-
viously described [20]. DNA was isolated from tissue
cores using the DNeasy tissue kit (Qiagen, Valencia, CA)
according to the manufacturer’s instructions. For the
detection of mutations, DNA was amplified with primers
flanking exon 3 of the HRAS gene (forward primer 5′-
GTC CTC CTG CAG GAT TCC TA -3′ and reverse
primer 5′- CGG GGT TCA CCT GTA CT -3′), exon 9
of the PIK3CA gene (forward primer 5′- TGA AAA TGT
ATT TGC TTT TTC TGT -3′ and reverse primer 5′-
TGT AAA TTC TGC TTT ATT TAT TCC -3′) and exon
20 of the PIK3CA gene (forward primer 5′- TTT GCT
CCA AAC TGA CCA A -3′ and reverse primer 5′- GCA
TGC TGT TTA ATT GTG TGG -3′). PCR products were
sequenced in both sense and antisense directions using the
BigDye Terminator v3.1 cycle sequencing kit on ABI 3730
(Applied Biosystems, Inc., Foster City, CA) according to the
manufacturer’s instructions (Additional file 1: Figure S1 and
Additional file 2: Figure S2). The sequences were analyzed
using Mutation Surveyor software (SoftGenetics, LLC.,
State College, PA).The presence of most common PIK3CA mutations
(p.E545K and p.E542K) was confirmed by SNaPshot PCR as
per the manufacturer’s manual and as previously described
[21] (Additional file 3: Figure S3). Briefly, primers for exon
9 (forward 5′-AGTAACAGACTAGCTAGAGA-3′ and
reverse 5′-ATTTTAGCACTTACCTGTGAC-3′) and exon
20 (forward 5′-GACCCTAGCCTTAGATAAAAC-3′ and
reverse 5′-GTGGAAGATCCAATCCATTT-3′) were used
for amplification. Denatured products were analyzed on an
ABI 3730 DNA analyzer (Applied Biosystems, Foster City,
CA, USA).
PTEN and PIK3CA fluorescence in situ hybridization (FISH)
Cases with known wild type PIK3CA and HRAS and avail-
able tissue were tested for PIK3CA and PTEN copy number
changes by FISH (n = 22) (Additional file 4: Figure S4). Sixty
to 130 cells were analyzed. PTEN (SpectrumOrange) and
chromosomal enumeration probe 10 (CEP10, Spectrum
Green) FISH was performed as per manufacturer’s rec-
ommendations (Abbot Molecular, Des Plaines, IL, USA)
and as previously described [22]. Results were interpreted
using previously established thresholds [23,24]: PTEN
homozygous deletion was defined as >20% of cells without
PTEN locus signal and the presence of ≥2 CEP10 signals.
Hemizygous PTEN deletion was defined as >30% of cells
with only one PTEN signal and the presence of ≥2 CEP10
signals. As previously suggested, cases with >50% of
cells with a single CEP10 signal were categorized as
“Chromosome 10 monosomy”, an additional mechan-
ism of PTEN loss [22]. Despite repeated hybridization
attempts, no data were obtained in one case.
PIK3CA (Spectrum Green) and CEP3 (Spectrum Orange)
(Abbot Molecular, Des Plaines, IL, USA) FISH was per-
formed as per manufacture’s recommendation. PIK3CA
amplification was defined as PIK3CA/CEP3 >2. Despite
repeated hybridization attempts, no data were obtained
in one case.
Statistical analysis
The primary endpoint was disease-specific survival (DSS) de-
fined as time elapsed from the date of diagnosis until death
from cancer. DSS was chosen as a primary endpoint over
the overall survival due to the predominance of patients
deceased from causes unrelated to the oropharyngeal SCC
(n = 21). DSS was assessed only for patients with > 2 months
of follow-up (n = 72). Patients who were alive at last follow-
up or had died from other causes were censored. Survival
data were presented as Kaplan-Meier plots. The log rank
test was used to test survival equality. Covariates examined
for association with survival included age, gender, smoking
(ever versus never), site (tonsil and base of tongue), T and N
classification, AJCC clinical stage, adjuvant chemotherapy or
radiotherapy. Cross-tabulated categorical data were tested
for independence with Fisher’s exact test.
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The clinicopathologic characteristics of 75 HPV-positive
oropharyngeal SCC patients are summarized in Table 1. The
mean follow-up was 122 months (minimum – maximum,
4–322). While 21 patients deceased of causes unrelated to
oropharyngeal SCC, 14 patients died of disease. The 3-year
disease specific survival (DSS) was 85%. In this clinico-
pathologically uniform group of patients only pathologic
tumor stage (pT) correlated with DSS (Figure 1A). For
instance, the DSS at 5 years was 87% for pT1 and 40%
for pT4 (p = 0.039). There was a trend toward a worse
DSS for patients with clinical stage IV disease; however, it
did not reach statistical significance, most likely due to theTable 1 Clinicopathologic features of patients with human pa
PIK3CA mutational status
Feature Total1,
n = 75
Men/women 64/11
Average age, years (range) 56 (34–78)
Smoking2 Never 22
Ever 40
Site3 BOT 31
Tonsil 43
pT4 1 34
2 25
3 7
4 5
pN6 0 2
1 16
2 51
3 5
Resection Margins5 Positive 10
Negative 54
Clinical Stage6 I 1
III 15
IV 58
Therapy7 RT 43
CRT 21
Non-keratinizing 52
Mixed 23
Deceased of disease 14
1For one patient with HRAS mutation PIK3CA status was indeterminate. The clinicop
presented in the columns 3 and 4 of the Table.
2Smoking history was not available for 13 patients.
3The oropharyngeal sub-site for one case was unknown.
4pT was unknown for 4 cases with biopsies only.
5Margin status was not assessed in 11 cases (biopsies, fragmented specimens).
6pN and clinical stage were unknown for 1 patient.
7Seven patients received no postoperative therapy; for 4 patients these data were n
BOT base of tongue, RT radiotherapy, CT chemotherapy, CRT chemoradiotherapy, mlow number of events in stage III patients (Figure 1B). It is
noteworthy that patients’ gender, age, smoking history,
oropharyngeal sub-site, pN, and treatment modality was
not associated with survival in these individuals.
PIK3CA, HRAS, and PTEN alterations
PIK3CA mutations were identified in 23 of 75 patients
with oropharyngeal SCC (31%), including exon 9 (p.E545K
[n = 10] and p.E542K [n = 5]) or exon 20 (p.H1047Y, n = 2)
mutations. Five cases with rare mutations and one case
with novel mutation are presented in Table 2. Patients’
gender, age, smoking history, oropharyngeal sub-site, pT,
pN, clinical stage, and treatment modality were similarpillomavirus positive oropharyngeal SCC, overall and by
PIK3CA wild type PIK3CA mutant Notes
n = 51 n = 23
43/8 20/3 n.s.
56 55.3 n.s.
15 7 n.s.
26 14
24 7 n.s.
27 15
23 11 n.s.
17 8
4 3
4 1
2 0 n.s.
11 5
35 15
3 2
7 3 n.s.
36 18
1 0 n.s.
10 4
40 18
32 11 n.s.
14 7
35 17 n.s.
17 5
9 5
athologic features of the case with indeterminate PIK3CA status are not
ot available.
ixed keratinizing and non-keratinizing, n.s. not statistically significant.
Figure 1 Disease specific survival (DSS) of patients with p16 and human papillomavirus positive oropharyngeal squamous cell
carcinoma. DSS was assessed only for patients with > 2 months of follow-up (n = 72). A. pT stage and disease specific survival. B. Clinical stage
and disease specific survival. C. PIK3CA mutational status and disease specific survival. D. Presumed activation of PI3K pathway and disease specific
survival. Cases with PI3K pathway activating alteration with < 2 months of follow-up were excluded from the DSS analysis.
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Disease specific survival (DSS) of the patients in these
two groups was not significantly different (Figure 1C).
HRAS mutation (c.182A > T, p.Q61L) was identified in
1 of 62 tested cases (or in 1 of 58 successfully tested
cases; in 4 cases the status of HRAS was indeterminate).
In the only case with HRAS mutation, the mutational
status of PIK3CA was indeterminate.Table 2 Rare and novel PIK3CA mutations in HPV positive oro
Mutation Clinicopathologic features and numbe
this study, n
Exon 9, c.1571G > A, p.R524K
and c.1573G > A, p.E525K
53 year old man, NK, pT1 N2, no postope
NED at 132 mo, n = 1
Exon 9, c.1610G > A, p.R537Q 60 year old man, NK, pT1 N2, CRT, DOD in 2
Exon 20, c.2975G > A, p.R992Q 68 year old man, NK, pT2 N1, radiotherap
70 months, n = 1
Exon 20, c.3103G > A, p.A1035T 54 year old man, mixed K& NK pT2 N2, ra
DOD at 53 months, n = 1
Exon 20, c.3129G > C, 48 year old man, mixed K & NK, pT3 N1,
NED at 284 months, n = 1
p.M1043I
Exon 20, c.3153G > A, p.W1051* 71 year old man, NK, pT1 N1, treated wit
DOC at 182 months, n = 1
NK non-keratinizing, K keratinizing, DOC deceased of other causes, DOD deceased oPIK3CA amplification was identified in 4 of 21 cases
(20%). PTEN loss was identified in 7 of 21 cases (33%)
(chromosome 10 monosomy [n = 4), homozygous deletion
[n = 3]; note, for one of the cases with homozygous deletion
clinical follow-up was not available).
Assuming that PIK3CA mutation or amplification,
HRAS mutation, or loss of PTEN lead to PI3K pathway
activation, patients with tumors harboring one of thesepharyngeal SCC
r of cases in Prior reports and References
rative therapy, None. While individually both mutations were previously
reported, the combination of the two was not.
2 months, n = 1 None
y, DOC at Glioblastoma multiforme, n = 1 [25]
diotherapy, Endometrial adenocarcinoma, n = 1 [26]
Urothelial carcinoma of the bladder, n =1 [27]
radiotherapy, Carcinoma of the breast, n = 2 [28]
h radiotherapy, Ovarian clear cell carcinoma, n = 1; conventional
colorectal carcinoma, n = 1; [29,30]
f disease, CRT chemoradiotherapy, NED no evidence of disease.
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and compared to patients whose tumors did not harbor
any of the above genetic alterations. PI3K pathway ac-
tivation did not correlate with DSS (Figure 1D).
Discussion
The clinical and pathologic characteristics of our HPV-
positive oropharyngeal SCC population and the per-
formance of conventional pathologic prognosticators
(e.g., pT, pN) are consistent with prior reports [31].
To our knowledge, this is the largest HPV-positive
oropharyngeal SCC cohort to undergo evaluation for
PIK3CA and HRAS mutation and PIK3CA and PTEN
amplification/loss. Our findings suggest that mutation
or amplification of PIK3CA may represent the most
common alteration in HPV-positive oropharyngeal SCC. It
is noteworthy that recent mutational analyses of head and
neck SCC also found PIK3CA alterations, albeit at lower
rates [10,11,15]. The variation in PIK3CA mutation inci-
dence is most likely due to the relative underrepresentation
of HPV-positive oropharyngeal SCC in other cohorts, use
of oropharyngeal site as a surrogate marker for HPV status,
and the use of different techniques to assess for PIK3CA
mutations. The recently published data [11,15] highlighted
an interesting phenomenon that even though HPV-positive
SCC harbored fewer mutations on average, as high as 20%
of HPV-positive SCC (3/15 cases [15]) harbored PIK3CA
mutation as the only cancer gene mutation, indicating that
PI3K pathway mutations are enriched in HPV-positive tu-
mors despite the lower rate of gene mutations in general.
The higher prevalence of PI3K pathway abnormalities in
oropharyngeal SCC was previously linked to HPV [8,9].
All mutations found in the samples of HPV-positive
oropharyngeal SCC were heterozygous with mutant al-
lelic frequency that appeared to range from 20% to
50% of alleles (corresponding to 40%– 100% of cancer
cells with a heterozygous mutation). None of the cases
showed mutant allelic frequency of more than 50%
suggesting that loss of the wild type PIK3CA allele or
amplification of the mutant PIK3CA allele in cancer
cells is exceedingly rare.
Although HRAS mutations have been reported to modu-
late signaling through the PI3K pathway [32,33], the role of
the mutation found in a single HPV-positive oropharyngeal
SCC in this study remains unclear.
PTEN is generally understood to function as a tumor
suppressor gene and to negatively regulate PI3K path-
way. Therefore, loss of PTEN should lead to PI3K path-
way activation. The incidence of PTEN alterations in
head and neck SCC varies in the literature and there is
little indication that PTEN loss has an independent
prognostic value [34,35]. We found that PTEN loss (as
assessed by FISH) was relatively common in HPV-
positive oropharyngeal SCC.Activation of the PI3K pathway, generally by virtue
of PIK3CA gene amplification, has been previously reported
to represent a poor prognostic biomarker in head and neck
SCC [36]. Others have reported that phosphorylation of
AKT, a downstream target of PIK3CA, is associated with
poor clinical outcome in oropharyngeal SCC, specifically
[37]. Although HPV status was not specifically assessed in
this cohort of oropharyngeal SCC, it is reasonable to pre-
sume that it was enriched for HPV-positive SCC. Our ana-
lysis showed no association between the genetic alterations
we assessed for (combined into a “PI3K activated” group)
and clinical outcome. Prior reports have generally focused
on a single alteration or biomarker assessment. It is possible
that some of the alterations we detected in HPV-positive
oropharyngeal SCC do not activate the pathway as pre-
dicted. Or, more likely, each alteration modulates PI3K
oncogenic signaling. Further functional studies in relevant
preclinical models are needed to decipher the precise con-
tribution of each mutation, amplification and/or loss to
PI3K pathway status in HPV-positive oropharyngeal SCC.
One of the technical limitations of this study is that
we restricted our assessment to exons 9 and 20 of
PIK3CA gene and we have likely underestimated the fre-
quency of PIK3CA mutation in this cohort. Similarly, we
only assessed codon 61 of HRAS and did not perform
codon 12/13 testing. Therefore, the actual mutation fre-
quency of both PIK3CA and HRAS could be higher than
reported here.
The variety of potential mechanisms leading to PI3K
pathway activation underscores the complexity of the
potential implications of our findings. It is possible, as
reported by others and us, that head and neck SCC har-
boring “driver” PIK3CA mutations demonstrate enhanced
response to PI3K pathway inhibitors [15,38,39]. Similar
findings have been reported in clinical trials of patients with
breast or gynecologic malignancies [40]. PI3K pathway
inhibitors are under early investigation in head and neck
SCC and clinical results are not yet available.
The EGFR monoclonal antibody cetuximab is FDA-
approved in both newly diagnosed head and neck SCC
as well as in the recurrent or metastatic setting [41].
We previously reported that PI3K pathway activation
correlates with clinical resistance to cetuximab in head
and neck SCC patients and targeting the PI3K pathway
enhanced the antitumor effects of EGFR inhibitors in
head and neck SCC preclinical models [42-44]. Therefore,
molecular determinants of PI3K activation may identify
individuals who may benefit from co-targeting of EGFR in
conjunction with PI3K pathway inhibition.
Conclusion
In conclusion, we report an analysis of a large HPV-positive
oropharyngeal SCC cohort and demonstrate distinct,
but perhaps functionally homologous, mechanisms of
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HRAS mutation, or PTEN loss. We provide evidence, for
the first time, of potentially activating genetic alterations
of the PI3K signaling pathway in about 45% (34/75) of
HPV-positive oropharyngeal SCC. The significance of the
affected PIK3CA exon or specific PIK3CA mutation types,
mechanism of PTEN loss, and the association with alter-
native mechanisms of PI3K signaling remain incompletely
understood. Our findings offer a molecular basis for future
studies of therapeutic targeting of PI3K pathway in HPV-
positive oropharyngeal SCC.
Additional files
Additional file 1: Figure S1. Representative cases of human
papillomavirus-positive oropharyngeal squamous cell carcinoma, with
HRAS (A) or PIK3CA mutations (B through I), sequencing electropherograms
(SE). Portions of the SE surrounding the point mutation were scanned.
A. HRAS c.182A>T, p.Q61L. B. PIK3CA, exon 9, c.1571G>A, p.R524K and
c.1573G>A, p.E525K. C. PIK3CA, exon 20, c.3103G>A, p.A1035T. D. PIK3CA,
exon 20, c.3129G>C, p.M1043I. E. PIK3CA, exon 20, c.3139C>T, p.H1047Y.
F. PIK3CA, exon 20, c.3153G>A, p.W1051*.G. PIK3CA, exon 9, c.1633G>A,
p.E545K. H. PIK3CA, exon 9, c.1610G>A, p.R537Q. I. PIK3CA, exon 20,
c.2975G>A, p.R992Q.
Additional file 2: Figure S2. Representative sequencing
electropherograms (SE) illustrating PIK3CA mutations. The entirely
scanned SE are presented to illustrate low background.
Additional file 3: Figure S3. SNaPshot detection of common hotspot
mutations in the exon 9 of the PIK3CA gene. SNaPshot result illustrating c.
1633G>A, p.E545K electropherogram pattern (mutant peak is indicated
by a grey arrow). The bases are color-coded: “A” – green, while “G” – blue.
The red trigon-shaped peaks represent internal size standards.
Additional file 4: Figure S4. Representative images of PTEN and PIK3CA
fluorescence in situ hybridization, FISH, original magnification 1000x. All
cases included in this figure are oropharyngeal squamous cell carcinoma
that are human papillomavirus-positive, HRAS wild-type, PIK3CA wild-type,
without PIK3CA amplification. The nuclei were counterstained with DAPI/
Antifade 1 (blue) (Vysis, Inc., Downers Grove, IL). A. PTEN FISH, representative
field: most nuclei are characterized by two PTEN signals (orange) and two
chromosomal enumeration probe 10 (CEP10) signals (green), consistent
with normal PTEN copy number. B. PTEN FISH, representative field: 57.1% of
cells (36/63) showed only one pair of PTEN and CEP10 signals, consistent
with chromosome 10 monosomy. C. PTEN FISH, representative field:
90.2% (55/61) of analyzed cells showed no PTEN signal, consistent with
homozygous PTEN loss. Also, 55.7% (34/61) of analyzed cells showed
only one CEP 10 signal consistent with chromosome 10 monosomy. The
PTEN/CEP10 ratio was 0.11. D. PIK3CA (green) and CEP3 (orange) FISH,
representative field. The PIK3CA/CEP3 ratio is 2.5.
Competing interests
P50CA97190 and the American Cancer Society (to JRG) and the Patricia L.
Knebel Fund of the Pittsburgh Foundation (to VWYL).
Authors’ contributions
MM and AL carried out molecular genetic studies. SC, JRG, VWYL drafted the
manuscript. SC, MNN conceived, designed the study, and acquired the data.
SC performed the statistical analysis. All authors were involved in analysis
and interpretation of data and critical revision of the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
The authors wish to thank members of the Molecular Anatomic Pathology
and Developmental laboratories of the Department of Pathology, University
of Pittsburgh, for excellent technical support and Robyn Roche for
outstanding secretarial support. Dr. Chiosea would like to dedicate this paperto his parents, Ivan Chiosea and Feodora Chiosea, who are the source of
determination and discipline.
Author details
1Department of Pathology, University of Pittsburgh, 200 Lothrop St,
Pittsburgh, PA 15213, USA. 2Department of Otolaryngology, University of
Pittsburgh, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
Received: 2 June 2013 Accepted: 6 December 2013
Published: 17 December 2013
References
1. Woenckhaus J, Steger K, Werner E, Fenic I, Gamerdinger U, Dreyer T, Stahl U:
Genomic gain of PIK3CA and increased expression of p110alpha are
associated with progression of dysplasia into invasive squamous cell
carcinoma. J Pathol 2002, 198(3):335–342.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH: The molecular biology of head
and neck cancer. Nat Rev Cancer 2011, 11(1):9–22.
3. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N: Oncogenic
mutations of the PIK3CA gene in head and neck squamous cell
carcinomas. Int J Oncol 2008, 32(1):101–111.
4. Murugan AK, Munirajan AK, Tsuchida N: Ras oncogenes in oral cancer:
the past 20 years. Oral Oncol 2012, 48(5):383–392.
5. Qiu W, Tong GX, Manolidis S, Close LG, Assaad AM, Su GH: Novel
mutant-enriched sequencing identified high frequency of PIK3CA
mutations in pharyngeal cancer. Int J Cancer 2008, 122(5):1189–1194.
6. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B,
Goodman MT, Sibug-Saber M, Cozen W, et al: Human papillomavirus and
rising oropharyngeal cancer incidence in the United States. J Clin Oncol
2011, 29(32):4294–4301.
7. Chenevert J, Chiosea S: Incidence of human papillomavirus in
oropharyngeal squamous cell carcinomas: now and 50 years ago.
Hum Pathol 2012, 43(1):17–22.
8. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa
J: PIK3CA mutation is an oncogenic aberration at advanced stages of
oral squamous cell carcinoma. Cancer Sci 2006, 97(12):1351–1358.
9. Won HS, Jung CK, Chun SH, Kang JH, Kim YS, Sun DI, Kim MS: Difference in
expression of EGFR, pAkt, and PTEN between oropharyngeal and oral
cavity squamous cell carcinoma. Oral Oncol 2012, 48(10):985–990.
10. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry
C, Xie TX, Zhang J, Wang J, et al: Exome sequencing of head and neck
squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Science 2011, 333(6046):1154–1157.
11. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A,
Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al: The mutational
landscape of head and neck squamous cell carcinoma. Science 2011,
333(6046):1157–1160.
12. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek V, Fu S, Piha-Paul
SA, Lee JJ, Luthra R, et al: PIK3CA mutation H1047R is associated with response
to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials.
Cancer Res 2013, 73(1):276–284.
13. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD,
Delgado L, Taylor A, Lupinacci L, et al: First-in-man clinical trial of the oral
pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
J Clin Oncol 2011, 29(35):4688–4695.
14. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes
JH, Weckstein D, Elfiky A, Sims DM, et al: Phase II trial of RAD001 and
bicalutamide for castration-resistant prostate cancer. BJU Int 2012,
110(11):1729–1735.
15. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q,
Du Y, Gilbert B, et al: Frequent mutation of the PI3K pathway in head and
neck cancer defines predictive biomarkers. Cancer Discov 2013, 3(7):761–769.
16. Rodriguez-Viciana P, Warne PH, Vanhaesebroeck B, Waterfield MD,
Downward J: Activation of phosphoinositide 3-kinase by interaction with
Ras and by point mutation. Embo J 1996, 15(10):2442–2451.
17. Espada J, Perez-Moreno M, Braga VM, Rodriguez-Viciana P, Cano A: H-Ras
activation promotes cytoplasmic accumulation and phosphoinositide
3-OH kinase association of beta-catenin in epidermal keratinocytes.
J Cell Biol 1999, 146(5):967–980.
18. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL: The PTEN/MMAC1
tumor suppressor phosphatase functions as a negative regulator of the
Chiosea et al. BMC Cancer 2013, 13:602 Page 7 of 7
http://www.biomedcentral.com/1471-2407/13/602phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998,
95(26):15587–15591.
19. Singhi AD, Westra WH: Comparison of human papillomavirus in situ
hybridization and p16 immunohistochemistry in the detection of human
papillomavirus-associated head and neck cancer based on a prospective
clinical experience. Cancer 2010, 116(9):2166–2173.
20. Prince ME, Ubell ML, Castro J, Ogawa H, Ogawa T, Narayan A, Paulino A,
Cole A, Wolf GT, Rubin MA, et al: Tissue-preserving approach to extracting
DNA from paraffin-embedded specimens using tissue microarray tech-
nology. Head Neck 2007, 29(5):465–471.
21. Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA: A SNaPshot
assay for the rapid and simple detection of four common hotspot codon
mutations in the PIK3CA gene. BMC Res Notes 2009, 2:66.
22. Pollack IF, Hamilton RL, James CD, Finkelstein SD, Burnham J, Yates AJ,
Holmes EJ, Zhou T, Finlay JL: Rarity of PTEN deletions and EGFR
amplification in malignant gliomas of childhood: results from the Children’s
Cancer Group 945 cohort. J Neurosurg 2006, 105(5 Suppl):418–424.
23. Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, Kuhnel T, Gosau M,
Zeitler K, Schwarz S, et al: Loss of PTEN is associated with elevated EGFR
and HER2 expression and worse prognosis in salivary gland cancer.
Br J Cancer 2012, 106(4):719–726.
24. Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A,
Alvarez K, Chen G, Darnel AD, Aprikian AG, et al: PTEN genomic deletion is
associated with p-Akt and AR signalling in poorer outcome, hormone
refractory prostate cancer. J Pathol 2009, 218(4):505–513.
25. Derakhshandeh-Peykar P, Alivi J, Hossein-nezhad A, Rautenstrauss B, Vesal
RE, Doriani A: High frequency of mutations in the PIK3CA gene helical
and kinase coding regions in a group of Iranian patients with high-grade
glioblastomas: five novel mutations. J Neurogenet 2011, 25(4):189–194.
26. Catasus L, Gallardo A, Cuatrecasas M, Prat J: PIK3CA mutations in the kinase
domain (exon 20) of uterine endometrial adenocarcinomas are associated
with adverse prognostic parameters. Mod Pathol 2008, 21(2):131–139.
27. Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I,
Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, et al: A comprehensive
immunohistochemical and molecular approach to the PI3K/AKT/mTOR
(phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/
mammalian target of rapamycin) pathway in bladder urothelial
carcinoma. BJU Int 2012, 110(11 Pt C):E1237–E1248.
28. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty
PM, Bourgon R, Zheng J, et al: Diverse somatic mutation patterns and
pathway alterations in human cancers. Nature 2010, 466(7308):869–873.
29. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D,
Velculescu VE, Kuman RJ, et al: Frequent activating mutations of PIK3CA in
ovarian clear cell carcinoma. Am J Pathol 2009, 174(5):1597–1601.
30. Garcia-Solano J, Conesa-Zamora P, Carbonell P, Trujillo-Santos J, Torres-Moreno
DD, Pagan-Gomez I, Rodriguez-Braun E, Perez-Guillermo M: Colorectal serrated
adenocarcinoma shows a different profile of oncogene mutations, MSI
status and DNA repair protein expression compared to conventional and
sporadic MSI-H carcinomas. Int J Cancer 2012, 131(8):1790–1799.
31. Sinha P, Lewis JS Jr, Piccirillo JF, Kallogjeri D, Haughey BH: Extracapsular
spread and adjuvant therapy in human papillomavirus-related, p16-positive
oropharyngeal carcinoma. Cancer 2012, 118(14):3519–3530.
32. Gripp KW, Bifeld E, Stabley DL, Hopkins E, Meien S, Vinette K, Sol-Church K,
Rosenberger G: A novel HRAS substitution (c.266C>G; p.S89C) resulting in
decreased downstream signaling suggests a new dimension of RAS
pathway dysregulation in human development. Am J Med Genet A 2012,
158A(9):2106–2118.
33. Juanpere N, Agell L, Lorenzo M, de Muga S, Lopez-Vilaro L, Murillo R, Mojal
S, Serrano S, Lorente JA, Lloreta J, et al: Mutations in FGFR3 and PIK3CA,
singly or combined with RAS and AKT1, are associated with AKT but not
with MAPK pathway activation in urothelial bladder cancer. Hum Pathol
2012, 43(10):1573–1582.
34. Mavros A, Hahn M, Wieland I, Koy S, Koufaki ON, Strelocke K, Koch R,
Haroske G, Schackert HK, Eckelt U: Infrequent genetic alterations of the
tumor suppressor gene PTEN/MMAC1 in squamous cell carcinoma of the
oral cavity. J Oral Pathol Med 2002, 31(5):270–276.
35. Lee JI, Soria JC, Hassan KA, El-Naggar AK, Tang X, Liu DD, Hong WK, Mao L:
Loss of PTEN expression as a prognostic marker for tongue cancer.
Arch Otolaryngol Head Neck Surg 2001, 127(12):1441–1445.
36. Suda T, Hama T, Kondo S, Yuza Y, Yoshikawa M, Urashima M, Kato T,
Moriyama H: Copy number amplification of the PIK3CA gene isassociated with poor prognosis in non-lymph node metastatic head and
neck squamous cell carcinoma. BMC Cancer 2012, 12:416.
37. Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D,
Camp R, Rimm D, Vairaktaris E, et al: Phosphorylation of Akt (Ser473)
predicts poor clinical outcome in oropharyngeal squamous cell cancer.
Cancer Epidemiol Biomarkers Prev 2007, 16(3):553–558.
38. Erlich RB, Kherrouche Z, Rickwood D, Endo-Munoz L, Cameron S, Dahler A,
Hazar-Rethinam M, de Long LM, Wooley K, Guminski A, et al: Preclinical
evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in
head and neck squamous cell carcinoma. Br J Cancer 2012, 106(1):107–115.
39. Knowles JA, Golden B, Yan L, Carroll WR, Helman EE, Rosenthal EL:
Disruption of the AKT pathway inhibits metastasis in an orthotopic
model of head and neck squamous cell carcinoma. Laryngoscope 2011,
121(11):2359–2365.
40. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S,
Falchook GS, Hong DS, Garrido-Laguna I, et al: PI3K/AKT/mTOR inhibitors
in patients with breast and gynecologic malignancies harboring PIK3CA
mutations. J Clin Oncol 2012, 30(8):777–782.
41. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM,
Drenning SD, Tweardy DJ: Levels of TGF-alpha and EGFR protein in head
and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst
1998, 90(11):824–832.
42. Zhang X, Guo A, Yu J, Possemato A, Chen Y, Zheng W, Polakiewicz RD,
Kinzler KW, Vogelstein B, Velculescu VE, et al: Identification of STAT3 as a
substrate of receptor protein tyrosine phosphatase T. Proc Natl Acad Sci
USA 2007, 104(10):4060–4064.
43. Bhola NE, Thomas SM, Freilino M, Joyce S, Sahu A, Maxwell J, Argiris A,
Seethala R, Grandis JR: Targeting GPCR-mediated p70S6K activity may
improve head and neck cancer response to cetuximab. Clin Cancer Res
2011, 17(15):4996–5004.
44. Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen
CS, Grandis JR: Antitumor mechanisms of targeting the PDK1 pathway in
head and neck cancer. Mol Cancer Ther 2012, 11(6):1236–1246.
doi:10.1186/1471-2407-13-602
Cite this article as: Chiosea et al.: PIK3CA, HRAS and PTEN in human
papillomavirus positive oropharyngeal squamous cell carcinoma. BMC
Cancer 2013 13:602.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
